ALPMF
Astellas Pharma Inc.
Set alert
14.27 USD -3.13 -17.99%
15.00 Day range 15.00
10.00 52-week range 17.85
- YTD
- +8.35%
- 1 year
- +28.91%
- Open
- 15.00
- Prev close
- 17.40
- Mkt cap
- 25.59B
- Vol
- 341
- Avg vol
- 5.61K
- EPS
- 1.32
- P/E
- 10.81
More statistics
- Low
- 15.00
- High
- 15.00
- Earnings
- Nov 4, 2026
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.3937.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.3937 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.3327 | 0.4867 | +0.15 | +46.29% |
| Apr 27, 2026 | Mar 31, 2026 | 0.1926 | 0.153 | -0.04 | -20.56% |
| Feb 4, 2026 | Dec 31, 2025 | 0.2931 | 0.3576 | +0.06 | +22.01% |
| Oct 30, 2025 | Sep 30, 2025 | 0.2015 | 0.2989 | +0.10 | +48.34% |
| Jul 30, 2025 | Jun 30, 2025 | 0.1379 | 0.2652 | +0.13 | +92.31% |
News
- Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
- Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors
- Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer
- Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
- Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
- Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
- These Analysts Boost Their Forecasts On Vir Biotechnology
- What's Going On With Kyntra Bio Stock Tuesday?
- Vir Biotechnology Stock Hits 52-Week High Tuesday - Here's Why
- Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
Your note
Sign in to keep a note on ALPMF — it syncs with the Stock Master app.